Entera Bio Ltd. (ENTX) Stock Price & Analysis

Entera Bio Ltd. (ENTX) closed at USD 3.02 on Thursday, October 22, 2026, down 0.98% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 3.05; the Oct 22, 2026 session ranged USD 2.92–3.04 on volume of 629,443 shares. Market capitalization is $524.98M, with a 52-week range of USD 0.91–4.2 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:31 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ENTX.md

Key facts (ENTX)

• Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$17.0M, free cash flow -$11.0M (SEC filings).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 9.75 (range 9–11).
• Total return with dividends: 1Y +41.1% vs S&P 500 +14.9%; 5Y -29.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-13, EPS estimate USD -0.07, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ENTX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ENTX)

P/B 72.3x · FCF yield -2.09% · Earnings yield -3.24%

Analysts (ENTX)

Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 9.75 (low 9, high 11).

Rating changes, last 120 days:

Total return (dividends reinvested) (ENTX)

ENTX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 27, 2026.

Companies that name ENTX in their SEC reports

ENTX company outlook (results filed Aug 7, 2026)

• “Entera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028. ·”
• “EB618 was well tolerated at doses exceeding the anticipated clinical dose range by more than tenfold.”
• “As previously disclosed, Entera expects to evaluate the initiation of EB618 clinical development pursuant to analysis of the Phase 1 SAD/MAD studies of subcutaneous injectable OXM being conducted by OPKO.”
• “The net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through the anticipated submission of NDA to the FDA, advance EB612 into the clinic in collaboration with OPKO and extend the Company's cash runway into 2030. ·”

Quoted word-for-word from the SEC 8-K results press release.

ENTX analyst estimates and revisions

ENTX options: expected move

Options price a move of about ±38.1% (±$1.15) by Nov 20, 2026, which includes earnings on Nov 13, 2026. Over the last 8 reports the stock moved ±5.4% on average.

30-day implied volatility 156.3% vs 66.6% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:31 UTC)

Technical Analysis (ENTX)

Nexqual's technical model rates ENTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:31 UTC.

Analyst Ratings (ENTX)

Wall Street analysts rate ENTX "Buy" based on 5 analysts, with a mean price target of USD 9.75 (range USD 9–11), per Nexqual as of October 23, 2026 at 10:31 UTC.

Earnings (ENTX)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:31 UTC.

Financials & Fundamentals (ENTX)

Source: Nexqual, October 23, 2026 at 10:31 UTC.

Financial Health Score (ENTX)

Nexqual rates Entera Bio Ltd.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:31 UTC.

Ownership (ENTX)

Source: Nexqual, October 23, 2026 at 10:31 UTC.

Leadership (ENTX)

Entera Bio Ltd. is led by Miranda J. Toledano, CEO & Director, per Nexqual as of October 23, 2026 at 10:31 UTC.

Major Backers & Investors (ENTX)

Notable institutional backers of Entera Bio Ltd. include Knoll Capital Management, LLC, BVF Inc., Siren, L.L.C., according to Nexqual as of October 23, 2026 at 10:31 UTC.

Active Investors

Source: Nexqual, October 23, 2026 at 10:31 UTC.

From Entera Bio Ltd.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe that the granted patents as well as certain of the pending claims contained in our patent applications, if issued in substantially the same form, would cover our proprietary platform (N-Tab®) and the candidates used in various pipeline programs as indicated in the table below.
• We seek to protect our proprietary technology, in part, by entering into confidentiality agreements with our employees, consultants, contractors, manufacturers, outside scientific collaborators and sponsored researchers, members of our board of directors (the "Board"), technical review board and other advisors upon their engagement.
• We have received grants of approximately $0.5 million from the IIA to partially fund our PTH research and development for Osteoporosis.
• Our success depends in part on our ability to protect the proprietary nature of our product candidates, technology, and know-how; operate without infringing on the proprietary rights of others and preventing others from infringing on our proprietary rights.

Partnerships

• In December 2025, we announced new in vivo PK/PD data supporting the development of a proprietary long-acting PTH (LA-PTH) analog, which is being developed as part of a material transfer and collaboration agreement with OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. ("OPKO"), utilizing our N-Tab® platform.
• In February 2026, we entered into an amended and restated collaboration agreement with OPKO (the "A&R Collaboration Agreement) which amends and restates the 2025 Collaboration Agreement to expand the scope of the agreement to include the collaboration with respect to the preclinical and clinical development of a daily LA-PTH for the treatment of hypoparathyroidism and other indications in addition to the original oral dual agonist GLP-1/glucagon peptide program.

Legal & Regulatory Risks (Item 1A, quoted)

• The commencement and completion of clinical trials can be delayed or prevented for a number of reasons.
• The results of previous clinical trials may not be predictive of future results, our progress in trials for one product candidate may not be indicative of progress in trials for other product candidates, and our trials may not be designed so as to support regulatory approval.
• The design of a clinical trial can determine whether its results will support approval of a product.
• We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad, and compliance with such regulation may be expensive and consume substantial financial and management resources.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:31 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt